NAARDEN, the Netherlands and MIAMI, May 03, 2024 NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of.
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin